Drug‑induced hemolytic anemia
https://doi.org/10.33667/2078-5631-2021-1-49-56
Abstract
One of the reasons for the development of hemolytic anemia (HA) can be drugs, including some antibacterial, non-steroidal anti-inflammatory, antitumor and antihypertensive drugs. It was found that the most common drug-induced hemolytic anemia (DIHA) develops against the background of taking antibacterial drugs. The true prevalence of DIHA is not known and is approximately one case per 1.0–1.2 million patients. The mechanisms of the occurrence of DIHA are divided into immune and metabolic (non-immune). The first mechanism is associated with the formation of haptens, the second option – with the formation of immune complexes, the third option is mediated by the formation of true autoantibodies to red blood cells, the fourth option of the immune mechanism of the occurrence of DIHA is non-immunological protein absorption on the membranes of red blood cells. The risk factors for the development of DIHA are not fully established. The most common hereditary risk factor for DIHA is glucose-6-phosphate dehydrogenase deficiency. The main method of diagnosing DIHA is a direct antiglobulin test (direct Coombs’ test). The temporal relationship between the use of the inducer drug and the development of HA symptoms is important. The treatment strategy of DIHA is determined by the severity of the disease. In all cases, treatment should be initiated with the identification and withdrawal of the drug that initiated the occurrence of HA. With the development of severe HA, hemodialysis may be required. Prevention of DIHA involves avoiding the use of drugs associated with a high risk of its development.
About the Authors
O. D. Ostroumova
Russian Medical Academy for Postgraduate Continuous Education
Russian Federation
Russian Federation
Ostroumova Olga D.
Moscow
S. A. Bliznyuk
City Clinical Hospital n. a. S. P. Botkin
Russian Federation
Russian Federation
Bliznyuk Svetlana A.
Moscow
A. I. Kochetkov
Russian Medical Academy for Postgraduate Continuous Education
Russian Federation
Russian Federation
Kochetkov Alexey I.
Moscow
A. G. Komarova
City Clinical Hospital n. a. S. P. Botkin
Russian Federation
Russian Federation
Komarova Anna G.
Moscow
References
1. Qahtani S. A. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med 2018; 11 (6): 5501–5512.
2. Tisdale J. E., Miller D. A. Drug Induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda, Md.: American Society of Health-System Pharmacists; 2018; 1399 рр.
3. Quentin A. H., Robert S., Edwin M., John D. G., Drew P. and Anita H. on behalf of the British Society for Haematology Guidelines. Guidelines on the man agement of drug-induced immune and secondary autoimmune, haemolytic anaemia. British Journal of Haematology; 2017; 177(2): 208–220. https://doi.org/10.1111/bjh.14654
4. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010; 24 (4–5): 143–150. https://doi.org/10.1016/j.blre.2010.06.004.
5. Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012; 11 (4): 635–642. https://doi.org/10.1517/14740338.2012.678832
6. Jollow D. J., Bradshaw T. P., McMillan D. C. Dapsone-induced hemo lytic anemia. Drug Metab Rev. 1995; 27 (1–2): 107–124. https://doi.org/10.3109/03602539509029818.
7. Lewis C. R., Manoharan A. Pure red cell hypoplasia secondary to isoniazid. Postgrad Med J. 1987; 63 (738): 309–310. https://doi.org/10.1136/pgmj.63.738.309
8. Oh Y. R., Carr-Lopez S.M., Probasco J. M., Crawley P. G. Levofloxacin-induced autoimmune hemolytic anemia. 2003; 37 (7–8): 1010–1013. https://doi.org/10.1345/aph.1C525.
9. Johnson S. T., Fueger J. T., Gottschall J. L. One center’s experience: the serology and drugs associated with drug-induced immune hemolytic anemia – a new paradigm. Transfusion. 2007; 47 (4): 697–702. https://doi.org/10.1111/j.1537-2995.2007.01173.x.
10. Gehrs B. C., Friedberg R. C. Autoimmune hemolytic anemia. Am J Hematol. 2002; 69 (4): 258–271. https://doi.org/10.1002/ajh.10062.
11. Neunert C. E., Paranjape G. S., Cameron S., Rogers Z. R. Intravascular hemolysis following low dose daily rifampin, Pediatr Blood Cancer. 2008; 51 (6): 821–823. https://doi.org/10.1002/pbc.21709
12. de Leeuw N., Shapiro L., Lowenstein L. Drug-induced hemolytic anemia. Ann Intern Med. 1963; 58: 592–607. https://doi.org/10.7326/0003–4819–58–4–592.
13. Arndt P. A., Garratty G., Wolf C. E., Rivera M. Haemolytic anaemia and renal failure associated with antibodies to trimethoprim and Transfus Med. 2011; 21(3): 194–198. https://doi.org/10.1111/j.1365–3148.2010.01061.x.
14. Taraszewski R., Harvey R., Rosman P. Death from drug-induced hemolytic anemia. Postgrad Med. 1989; 85 (7): 79–84. https://doi.org/10.1080/00325481.1989.11700719
15. Ibrahim I. H., Sallam S. M., Omar H., Rizk M. Oxidative hemolysis of erythrocytes induced by various vitamins. Int J Biomed Sci. 2006; 2 (3): 295–298.
16. Danielson D. A., Douglas S. W., Herzog P. et al. Drug-induced blood dis orders. JAMA. 1984; 252 (23): 3257–3260. https://doi.org/10.1001/jama.1984.03350230017024
17. Cerynik D. L., Lee G. C., Fayssoux R., Amin N. H. Case report: cefazolin-induced hemolytic anemia. Clin Orthop Relat Res. 2007; 459: 260–262. https://doi.org/10.1097/blo.0b013e31803d3aad
18. Moake J., Butler C. F., Hewell G. M. et al. Hemolysis induced by cefazoline and cephalothin in a patient with penicillin sensitivity. Transfusion. 1978; 18 (3): 369–373. https://doi.org/10.1046/j.1537–2995.1978.18378205151.x.
19. Shulman I. A., Arndt P. A., McGehee W., Garratty G. Cefotaxime induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism, Transfusion. 1990; 30 (3): 263–266. https://doi.org/10.1046/j.1537–2995.1990.30390194351.x.
20. Moes G. S., MacPherson B. R. Cefotetan-induced hemolytic anemia: a case report and review of the literature. Arch Pathol Lab Med. 2000; 124 (9): 1344–1346. https://doi.org/10.1043/0003–9985(2000)124<1344:CIHA>2.0.CO;2.
21. Chenoweth C. E., Judd W. J., Steiner E. A., Kaufmann C. A. Cefotetan-induced immune hemolytic anemia. Clin Infect Dis. 1992; 15 (5): 863–865. https://doi.org/10.1093/clind/15.5.863.
22. Franchini M., Piccoli P. L., Gandini G. et al. Clinical and laboratory study of an episode of cefotetan-induced severe hemolitic anemia. Hematology. 2004; 9(1): 65–69. https://doi.org/10.1080/10245330310001638956.
23. Stroncek D., Procter J. L., Johnson J. Drug-induced hemolysis: cefotetan-depended hemolytic anemia mimicking an acute intravascular immune transfusion reaction. Am J Hematol. 2000; 64 (1): 67–70. https://doi.org/10.1002/(SICI)1096–8652(200005)64:1<67:AID-AJH12>3.0.CO;2-Z
24. Endoh T., Yagihashi A., Sasaku M., Watanabe N. Ceftizoxime-induced hemolysis due to immune complexes: case report and determination of the epitope responsible for immune complex-mediated hemolysis. Tranfusion. 1999; 39 (3): 306–309. https://doi.org/10.1046/j.1537–2995.1999.39399219289.x.
25. Longo F., Hastier P., Buckey M. J. et al. Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol. 1998; 93 (5): 836–837. https://doi.org/10.1111/j.1572–0241.1998.239_a.x.
26. Lim S., Alam M. G. Ciprofloxacin-induced acute interstitial nephritis and autoimmune hemolytic anemia. Ren Fail. 2003; 25 (4): 647–651. https://doi.org/10.1081/jdi-120022557.
27. Del Vasto F., Pinta M. F., Marchese L. et al. Drug-induced immune hemolytic hemolytic anemia in an 18-month-old patient. Responsible agent: erythromycin. Pediatr Med Chir. 1990; 12: 275–276.
28. Sykia A., Gigi E., Sinakos E. et al. Severe autoimmune hemolytic anemia complicated with liver decompensation and invasive aspergillosis in a patient with chronic hepatitis C during treatment with peg-interferon-a and ribavirin. J Gastrointestin Liver Dis. 2009; 18 (1): 118–119.
29. Itoh Y., Okanoue T. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients. J Gastroenterol. 2004; 39 (7): 704–705. https://doi.org/10.1007/s00535–004–1391–0.
30. Mary J. Y., Guiguet M., Baumelou E. Drug use and aplastic anaemia: the French experience. French Cooperative Group for the Epidemiological Study of the Aplastic Anaemia. Eur J Haematol Suppl. 1996; 57 (S 60): 35–41. https://doi.org/10.1111/j.1600–0609.1996.tb01643.x
31. Kramer M. R., Levene C., Hershko C. Severe reversible autoimmune haemolytic anaemia and thrombocytopenia associated with diclofenac therapy. Scand J Haematol. 1986; 36 (1): 118–120. https://doi.org/10.1111/j.1600–0609.1986.tb02662.x.
32. Guidry J. B., Ogburn C. L. Jr., Griffin F. M. Jr. Fatal autoimmune hemolytic anemia assorted with ibuprofen. JAMA. 1979; 242 (1): 68–69.
33. Kornberg A., Rachmilewitz E. A. Aplastic anemia after prolonged inges tion of indomethacin. Acta Haematol. 1982; 67 (2): 136–138. https://doi.org/10.1159/000207041.
34. Angeles M. I., Reid M. E., Yacob U. A. et al. Sulindac-induced immune hemolytic anemia. Transfusion. 1994; 34 (3): 255–258. https://doi.org/10.1046/j.1537-2995.1994.34394196626.x.
35. Cunha P. D., Lord R. S., Johnson S. T. et al. Immune hemolytic anemia caused by sensitivity to a metabolite of etodolac, a nonsteroidal anti-inflammatory drug. Transfusion. 2000; 40 (6): 663–668. https://doi.org/10.1046/j.1537-2995.2000.40060663.x.
36. Sklar G. E. Hemolysis as a potential complication of acetaminophen overdose in a patient with glucose - 6-phosphate dehydrogenase defi ciency. Pharmacotherapy. 2002; 22 (5): 656–658. https://doi.org/10.1592/phco.22.8.656.33216.
37. Sobotka J. L., Alexander B., Cook B. L. A review of carbamazepine’s hematologic reactions and monitoring recommendations. Dicp. 1990; 24 (12): 1214–1219. https://doi.org/10.1177/106002809002401214.
38. Moore N.C, Lerer B., Meyendorff E., Gershon S. Three cases of carbamazepine toxicity. A Sobm J Psychiatry. 1985; 142 (8): 974–975. https://doi.org/10.1176/ajp.142.8.974.
39. Blackburn S. C., Oliart A. D., Garcia Rodriguez L. A., Perez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy. 1998; 18(6): 1277–1283.
40. Trimble M. A., Sketch M. H. Jr, Mehta R. H. Hemolytic anemia: a rare but potentially serious adverse effect of captopril. Herz. 2007; 32 (1): 62–64. https://doi.org/10.1007/s00059–007–2956–5.
41. Carstairs K. C., Breckenridge A., Dollery C. T., Worlledge S. M. Incidence of a positive direct coombs test in patient oh alpha-methyldopa. Lancet. 1966; 2 (7455): 133–135. https://doi.org/10.1016/s0140–6736(66)92422–6.
42. Dacie S. J. The immune haemolytic anaemias: a century of exciting progress in understanding. Br J Haematol. 2001; 114 (4): 770–785. https://doi.org/10.1046/j.1365–2141.2001.02945.x.
43. Aymard J.P, Aymard B., Netter P. et al. Haematological adverse effects of histamine H2-receptor antagonists. Med Toxicol Adverse Drug Exp. 1988; 3 (6): 430–448. https://doi.org/10.1007/BF03259895.
44. Kirkiz S., Yarali N., Arman Bilir O., Tunc B. Metformin-induced hemolytic anemia, Med Princ Pract. 2014; 23 (2): 183–185. https://doi.org/10.1159/000356149
45. Hrisinko M. A., Chen Y. H., Rasburicase-induced Heinz body hemolytic anemia in a patient with chronic lymphocytic leukemia. Blood. 2015; 126 (6): 826. https://doi.org/10.1182/blood-2015–06–648576.
46. Nguyen A. P., Ness G. L. Hemolytic ane administration: a review of pub lished reports. J Pediatr Pharmacol Ther. 2014; 19 (4): 310–316. https://doi.org/10.5863/1551–6776–19.4.310.
47. Chang L. C., Kuo C. W., Chau T., Lin S. H. Phenazopyridine-induced hemolytic anemia in advanced kidney disease. J Am Geriatr Soc. 2014; 62 (12): 2464–2466. https://doi.org/10.1111/jgs.13161.
48. Siddiqui M. A. Chronic severe hemolytic anemia from phenazopyridine. Ann Intern Med. 1995; 122 (2): 156–157. https://doi.org/10.7326/0003–4819–122–2–199501150–00025
49. Petz L. D., Garratty G. Immune hemolytic anemias. 2nd ed. Philadelphia, PA: Churchill Livingston; 2004, 624 p.
50. Gehrs B. C., Friedberg R. C. Autoimmune hemolytic anemia. Am J Hematol. 2002; 69 (4): 258–271. https://dx.doi.org/10.1002/ajh.10062.
51. Qahtani S. Drug-induced megaloblastic, aplastic, and hemolytic anemias: current concepts of pathophysiology and treatment. Int J Clin Exp Med 2018; 11 (6): 5501–5512.
52. Ferner R. E. Drug-induced haemolytic anaemia, Adverse Drug Reaction Bulletin. 2012; 276 (1): 1063–1066. https://dx.doi.org/10.1097/FAD.0b013e32835aa06d
53. Megee F., O’Sullivan H., McCann S. R. Megaloblastosis and low-dose trimethoprim-sulfamethoxazole. Ann Intern Med. 1981; 95 (5): 657. https://dx.doi.org/10.7326/0003–4819–95–5–657_1.
54. Ackroyd J. F. The immunological basis of purpura due to drug hypersensitivity. Proc R Soc Med. 1962; 55 (1): 30–36. https://doi.org/10.1177/003591576205500109
55. Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012; 11 (4): 635–642. DOI: 10.1517/14740338.2012.678832.
56. Thomas A. Autoimmune hemolytic anemias. In: Lee G. R., Foerster J., Lukens J. et al., eds. Wintrobe’s clinical hemotology, 10th ed. Baltimore, MD: Wilkins, 1999: 1233–1263.
57. Greene E. M., Hagemann T. M. Drug-Induced Hematologic Disorders. In: Di Piro J. T., Talbert R. L., Yee G. C., Matzke G. R., Wells B. G., Posey L. eds. Pharmacotherapy: A Pathophysiologic Approach, 10e. McGraw-Hill. 2017. https://accesspharmacy.mhmedical.com/book.aspx?bookid=1861 Дата обращения 01.02.2021.
58. Aldomet (methyldopa) prescribing information. Canonsburg, PA: Mylan Pharmaceuticals Inc; 1998.
59. Garratty G., Petz L. D. Drug induced immune hemolytic anemia. Am J Med 1975; 58 (3): 398–407. https://dx.doi.org/10.1016/0002–9343(75)90606–3.
60. Salama A., Mayer B. Diagnostic pitfalls of drug-induced immune hemolytic anemia. Immunohematology 2014; 30 (2): 80–84.
61. McKenzie S. B. Hemolytic anemias due to extrinsic factors. In: McKenzie SB, ed. Textbook of Hematology. Baltimore: Williams & Wilkins; 1996; рр. 245–274.
62. Naranjo C., Busto U., Sellers E., Sandor P., Ruiz I., Roberts E., Janecek E., Domecq C., Greenblatt D. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981; 30 (2): 239–245. https://dx.doi.org/10.1038/clpt.1981.154
63. Sychev D. A., Ostroumova O. D., Pereverzev A. P. et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Farmateka. 2020; 27 (6): 113–126 (In Russ.) https://dx.doi.org/10.18565/pharmateca.2020.6.113–126
Review
For citations:
Ostroumova O.D., Bliznyuk S.A., Kochetkov A.I., Komarova A.G. Drug‑induced hemolytic anemia. Medical alphabet. 2021;(1):49-56. (In Russ.) https://doi.org/10.33667/2078-5631-2021-1-49-56
Views:
4801
Email this article 